• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

瑞波西汀在健康志愿者体内的药代动力学。单次口服剂量、线性关系及血浆蛋白结合率

Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding.

作者信息

Edwards D M, Pellizzoni C, Breuel H P, Berardi A, Castelli M G, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M

机构信息

Pharmacia-Farmitalia Carlo Erba, Pharmacokinetics and Metabolism, Milan, Italy.

出版信息

Biopharm Drug Dispos. 1995 Aug;16(6):443-60. doi: 10.1002/bdd.2510160603.

DOI:10.1002/bdd.2510160603
PMID:7579027
Abstract

The pharmacokinetics of reboxetine, a new antidepressant agent, were found to be close to linear in a crossover study comparing administration of single 2, 3, 4, and 5 mg capsule doses in 15 healthy male volunteers, and in the same study the capsules were bioequivalent to the proposed therapeutic tablet formulation (4 mg). Kinetic analysis was based on HPLC assay of reboxetine in plasma and urine collected up to 72 h after each administration. Plasma levels indicated a rapid absorption (tmax approximately equal to 2 h) and an elimination half-life of about 13 h. Clearance and volume of distribution were modest (ratios to bioavailability: CL/F approximately equal to 29 mL min-1; Vz/F approximately equal to 32 L); urinary excretion was approximately 9% of dose, corresponding to a renal clearance of only 3 mL min-1 (a value consistent with the rate of glomerular filtration of unbound drug). In vitro, binding to plasma proteins, estimated from radioactivity levels following dialysis of 14C-labelled reboxetine, appeared to be dominated by alpha 1-acid glycoprotein without marked saturation up to plasma concentrations of over 500 ng mL-1 (2.8-3.1% unbound with human plasma from three additional volunteers; 1.8-2.0% for 2 gL-1 orosomucoid alpha 1-acid glycoprotein, and 46.4-47.4% for 40 g L-1 albumin), whilst the mean Cmax in the current study was much lower (164 ng mL-1 after a 5mg dose).

摘要

在一项交叉研究中,对15名健康男性志愿者单次给予2、3、4和5毫克胶囊剂量的新型抗抑郁药瑞波西汀进行药代动力学研究,发现其药代动力学接近线性。在同一研究中,胶囊与拟用的治疗片剂剂型(4毫克)生物等效。动力学分析基于高效液相色谱法测定每次给药后72小时内采集的血浆和尿液中的瑞波西汀。血浆水平表明吸收迅速(达峰时间约为2小时),消除半衰期约为13小时。清除率和分布容积适中(与生物利用度的比值:CL/F约为29毫升/分钟;Vz/F约为32升);尿排泄量约为剂量的9%,对应肾清除率仅为3毫升/分钟(该值与未结合药物的肾小球滤过率一致)。在体外,根据14C标记的瑞波西汀透析后的放射性水平估计,与血浆蛋白的结合似乎主要由α1-酸性糖蛋白主导,在血浆浓度超过500纳克/毫升时无明显饱和现象(另外三名志愿者的人血浆中未结合率为2.8 - 3.1%;2克/升的类粘蛋白α1-酸性糖蛋白为1.8 - 2.0%,40克/升的白蛋白为46.4 - 47.4%),而本研究中的平均Cmax要低得多(5毫克剂量后为164纳克/毫升)。

相似文献

1
Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding.瑞波西汀在健康志愿者体内的药代动力学。单次口服剂量、线性关系及血浆蛋白结合率
Biopharm Drug Dispos. 1995 Aug;16(6):443-60. doi: 10.1002/bdd.2510160603.
2
Dose proportionality of reboxetine enantiomers in healthy male volunteers.
Biopharm Drug Dispos. 1999 May;20(4):177-81. doi: 10.1002/(sici)1099-081x(199905)20:4<177::aid-bdd172>3.0.co;2-i.
3
Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations.
Biopharm Drug Dispos. 1996 Oct;17(7):623-33. doi: 10.1002/(SICI)1099-081X(199610)17:7<623::AID-BDD978>3.0.CO;2-S.
4
Pharmacokinetics of reboxetine enantiomers in the dog.瑞波西汀对映体在犬体内的药代动力学。
Chirality. 1997;9(3):303-6. doi: 10.1002/(SICI)1520-636X(1997)9:3<303::AID-CHIR17>3.0.CO;2-R.
5
Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics.
Biopharm Drug Dispos. 1999 Jan;20(1):53-7. doi: 10.1002/(sici)1099-081x(199901)20:1<53::aid-bdd157>3.0.co;2-p.
6
Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
Clin Pharmacokinet. 2000 Dec;39(6):413-27. doi: 10.2165/00003088-200039060-00003.
7
Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans.酮康唑会抑制人体中抗抑郁药瑞波西汀对映体的清除。
Clin Pharmacol Ther. 1999 Oct;66(4):374-9. doi: 10.1053/cp.1999.v66.a101207.
8
Pharmacokinetics of reboxetine in healthy, elderly volunteers.瑞波西汀在健康老年志愿者体内的药代动力学。
Eur J Drug Metab Pharmacokinet. 2000 Jul-Dec;25(3-4):195-8. doi: 10.1007/BF03192313.
9
In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.健康志愿者中,来自双峰释放制剂的哌甲酯的体外溶出和体内口服吸收情况。
Biopharm Drug Dispos. 2004 Mar;25(2):91-8. doi: 10.1002/bdd.390.
10
Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents.瑞波西汀在不同种族健康志愿者中的药代动力学。
Psychopharmacology (Berl). 2001 May;155(2):148-53. doi: 10.1007/s002130100696.

引用本文的文献

1
Chirality of antidepressive drugs: an overview of stereoselectivity.抗抑郁药物的手性:立体选择性概述
Asian Biomed (Res Rev News). 2022 Apr 29;16(2):55-69. doi: 10.2478/abm-2022-0008. eCollection 2022 Apr.
2
Tianeptine interferes with microtubule organization and hormone secretion of pheochromocytoma cells.天冬普汀会干扰嗜铬细胞瘤细胞的微管组织和激素分泌。
Mol Cell Endocrinol. 2013 Dec 5;381(1-2):175-87. doi: 10.1016/j.mce.2013.07.033. Epub 2013 Aug 7.
3
Noradrenergic enhancement improves motor network connectivity in stroke patients.
去甲肾上腺素能增强改善中风患者的运动网络连通性。
Ann Neurol. 2011 Feb;69(2):375-88. doi: 10.1002/ana.22237. Epub 2010 Dec 28.
4
The role of the noradrenergic system in the exploration-exploitation trade-off: a psychopharmacological study.去甲肾上腺素能系统在探索-利用权衡中的作用:一项精神药理学研究。
Front Hum Neurosci. 2010 Aug 26;4:170. doi: 10.3389/fnhum.2010.00170. eCollection 2010.
5
Getting the balance right: Established and emerging therapies for major depressive disorders.把握平衡:治疗重度抑郁症的既有和新兴疗法。
Neuropsychiatr Dis Treat. 2010 Sep 7;6:343-64. doi: 10.2147/ndt.s10485.
6
Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study.血清素能和去甲肾上腺素能抗抑郁药在情绪表达解码过程中对面部情绪加工偏差的调节作用:一项事件相关电位(ERP)研究
Psychopharmacology (Berl). 2009 Mar;202(4):621-34. doi: 10.1007/s00213-008-1340-3. Epub 2008 Sep 30.
7
Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder.瑞波西汀与哌甲酯治疗儿童及青少年注意力缺陷多动障碍的对比研究
Eur Child Adolesc Psychiatry. 2009 Jan;18(1):53-9. doi: 10.1007/s00787-008-0705-9. Epub 2008 Jun 18.
8
Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant.瑞波西汀向母乳中的转移、其血浆浓度及对母乳喂养婴儿无不良反应。
Eur J Clin Pharmacol. 2006 Aug;62(8):633-8. doi: 10.1007/s00228-006-0140-0. Epub 2006 May 13.
9
The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.选择性去甲肾上腺素再摄取抑制剂抗抑郁药瑞波西汀:药理及临床概况。
CNS Drug Rev. 2004 Spring;10(1):23-44. doi: 10.1111/j.1527-3458.2004.tb00002.x.
10
Pharmacokinetics of reboxetine in healthy, elderly volunteers.瑞波西汀在健康老年志愿者体内的药代动力学。
Eur J Drug Metab Pharmacokinet. 2000 Jul-Dec;25(3-4):195-8. doi: 10.1007/BF03192313.